The Australian New Zealand Clinical Trials Registry (ANZCTR) is an online public registry of clinical trials based within the Evidence Integration Team at the CTC.

The Evidence Integration team uses the data publicly provided on the ANZCTR website to complete research on research (or meta-research). This includes research looking at the landscape or epidemiology of clinical trials, and exploring integrity, bias and methodology in research.

The team has recently completed an updated report looking at clinical trials activity within Australia, including activity of trials focussing on Indigenous health. This updated report, looking at trials registered from 2006-2020, can be found here. Future work will look at providing an update on clinical trials in New Zealand, with the previous report available here.

The team has recently published a guide for systematic reviewers searching clinical trials registers (available here) and is in the process of publishing work on data sharing practices in clinical trials.

Previous work looking at integrity and bias in clinical trials has looked at the impact of industry involvement of study characteristics, trends in registration practices, and differences in clinical trials registered prospectively on a registry such as the ANZCTR. Please see publications list below for more information.

The team welcomes any interest in research internships, and higher degrees such as Masters of Philosophy or PhD’s looking at meta-research, and research using data from registries such as the ANZCTR.

Contact us

For questions or comments directed at the ANZCTR: info@anzctr.org.au

For those interested in research internships or higher degrees please contact Professor Angela Webster.  

Publications

1. Willson ML*, Seidler AL*, Aberoumand M, Williams JG, Hunter KE, Barba A, Webster AC, Askie LM, Simes RJ. Latest update of the clinical trials landscape in Australia 2006 – 2020. Sydney: Australian New Zealand Clinical Trials Registry (*These authors contributed equally to this project.) https://doi.org/10.25910/t9n1-bm45
2. Hunter K, Webster A, Willson M, McDonald S, Berber S, Skeers P, Tan-Koay A, Parkhill A, Seidler AL. Searching clinical trials registers: guide for systematic reviewers. BMJ. 2022;377:e068791. https://doi.org/10.1136/bmj-2021-068791
3. Xu G, Modi D, Hunter KE, Askie LM, Jamieson LM, Brown A, Seidler AL. Landscape of clinical trial activity focusing on Indigenous health in Australia: an overview using clinical trial registry data from 2008-2018. BMC public health. 2022 Dec;22(1):1-1. https://doi.org/10.1186/s12889-022-13338-y
4. Tan, A. C., Askie, L. M., Hunter, K. E., Barba, A., Simes, R. J., & Seidler, A. L. Data sharing‐trialists’ plans at registration, attitudes, barriers and facilitators: a cohort study and cross‐sectional survey. Research Synthesis Methods 2021. https://doi.org/10.1002/jrsm.1500
5. Seidler AL, Aberoumand M, Williams JG, Tan A, Hunter KE, Webster A, Hunter K. The landscape of COVID-19 trials in Australia. The Medical Journal of Australia. 2021 May 4:1. https://doi.org/10.5694/mja2.51148
6. Seidler AL, Hunter KE, Chartres N, Askie LM. Associations between industry involvement and study characteristics at the time of trial registration in biomedical research. PLoS ONE 2019;14(9): e0222117. https://doi.org/10.1371/journal.pone.0222117
7. Tan A, Jiang I, Askie L, Hunter K, Simes RJ, Seidler AL. Prevalence of trial registration varies by study characteristics and risk of bias. J Clin Epi. 2019:113:64-74. https://doi.org/10.1016/j.jclinepi.2019.05.009  
8. Hunter KE, Seidler AL, Askie LM. Prospective registration trends, reasons for retrospective registration and mechanisms to increase prospective registration compliance: descriptive analysis and survey. BMJ Open 2018;8(3):e019983. doi: 10.1136/bmjopen-2017-019983. http://dx.doi.org/10.1136/bmjopen-2017-019983
9. Korevaar DA., Hooft L, Askie L, Barbour V, Faure H, Gatsonis C, Hunter KE, Kressel H, Lippman H, McInnes MM, Moher D, Rifai N, Cohen JF, and Bossuyt PMM. Facilitating Prospective Registration of Diagnostic Accuracy Studies: A STARD Initiative. Clin Chem. 2017, Aug;63(8):1331-1341. https://doi.org/10.1373/clinchem.2017.272765
10. Lam J, Lord SJ, Hunter KE, Simes RJ, Vu T, Askie LM. Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority Areas. Med J Aust. 2015 Jul 20; 203(2):97-101. https://doi.org/10.5694/mja14.00598
11. Hunter KE, Seidler AL,* Barba A, Wynn M, Berber S, Tan-Koay AG, Vu T, Simes RJ, Askie LM. The clinical trials landscape in New Zealand 2006–2015. Sydney: Australian New Zealand Clinical Trials Registry 2018. (* Hunter & Seidler contributed equally to this report). http://www.anzctr.org.au/docs/NZ_Report_2006-2015.pdf
12. Askie LM, Hunter KE, Berber S, Langford A, Tan-Koay AG, Vu T, Sausa R, Seidler AL, Ko H, Simes RJ. The clinical trials landscape in Australia 2006–2015. Sydney: Australian New Zealand Clinical Trials Registry 2017. http://www.anzctr.org.au/docs/ClinicalTrialsInAustralia2006-2015.pdf